Mantle Cell Lymphoma

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Latest News

BTK Inhibitor–Based Combinations Represent the Future of MCL Management

By Ashling Wahner

December 2nd 2024

Peter Martin, MD, discusses the current role of BTK inhibitors in MCL and how future research may solidify the use of these agents in this disease.

Vice Chair of the B-Cell Lymphomas NCCN Guidelines Maps Critical Changes From 2024

By Megan Hollasch
Caroline Seymour

December 2nd 2024

The OncFive: Top Oncology Articles for the Week of 11/17

By OncLive Staff

November 23rd 2024

BTK Inhibitors in Late-Relapse Mantle Cell Lymphoma | Image Credit: © Dr_Microbe - stock.adobe.com

Retrospective Data Show BTK Inhibitors May Be Optimal Second-Line Approach in Late-Relapse Mantle Cell Lymphoma

By Chris Ryan

November 19th 2024

Bendamustine/Obinutuzumab Induction in MCL

Bendamustine/Obinutuzumab Induction Generates Responses and MRD Negativity in Treatment-Naive MCL

By Ashling Wahner

November 18th 2024

Latest CME Events & Activities

26th Annual International Lung Cancer Congress®

July 25-26, 2025

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease

Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition

December 6, 2024

How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer

Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…

The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions

18th Annual New York GU Cancers Congress™

March 28-29, 2025

Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

20th Annual New York Lung Cancers Symposium®

November 15, 2025

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?

More News

Here is your guide to important regulatory approvals made by the FDA in May 2024.

OncLive’s May Roundup of Key FDA Approvals in Oncology

By Kristi Rosa

May 31st 2024

Here is your guide to important regulatory approvals made by the FDA in May 2024.

Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center

Dr Gordon on the FDA Approval of Liso-Cel in Relapsed/Refractory MCL

By Leo I. Gordon, MD

May 30th 2024

Leo I. Gordon, MD, discusses the significance of the FDA approval of liso-cel for patients with relapsed/refractory mantle cell lymphoma.

FDA Approves Liso-Cel for R/R Mantle Cell Lymphoma After 2 Lines of Therapy

By Chris Ryan

May 30th 2024

The FDA approved liso-cel for the treatment of adult patients with relapsed/refractory mantle cell lymphoma after at least 2 prior lines of therapy, including a BTK inhibitor.

MCL | Image Credit: ©freshidea - stock.adobe.com

Adding Ibrutinib to Chemoimmunotherapy Induction Improves FFS in Younger MCL

By Ryan Scott

May 20th 2024

The addition of ibrutinib to chemoimmunotherapy induction with ASCT improved rates of failure-free survival in younger patients with mantle cell lymphoma.

Dr Koff on Toxicities Associated With Pirtobrutinib in MCL

By Jean L. Koff, MD, MS

May 15th 2024

Jean L. Koff, MD, MS, discusses the toxicities associated with pirtobrutinib in the BRUIN trial for mantle cell lymphoma.

Gulrayz Ahmed, MD, the Medical College of Wisconsin

Retrospective Analysis Shows Efficacy and Safety of CAR T-Cell Therapy in MCL With SCNS

By Ashling Wahner

May 14th 2024

CAR T-cell therapy is effective and tolerable in patients with mantle cell lymphoma with secondary central nervous system involvement.

Jean L. Koff, MD, MS, Winship Cancer Institute

Efficacy and Safety of Pirtobrutinib Continue to Reshape MCL Treatment Paradigm

By Jax DiEugenio

May 13th 2024

Jean L. Koff, MD, MS, discusses key considerations in the choice of BTK inhibitors for frontline and maintenance treatment in MCL.

Frontline Acalabrutinib Plus Chemoimmunotherapy Elicits Meaningful Survival Benefit in MCL

By Kyle Doherty

May 2nd 2024

Acalabrutinib plus bendamustine and rituximab (BR) led to a statistically significant improvement in PFS vs BR for treatment-naive mantle cell lymphoma.

Dr Pearse on the Current Treatment Paradigm for Relapsed/Refractory MCL

By William B. Pearse, MD

April 18th 2024

William B. Pearse, MD, discusses the current treatment paradigm for patients with relapsed/refractory mantle cell lymphoma.

Zanubrutinib Associated With Longer Treatment Persistence, Duration, and TTD in Real-World MCL

By Ryan Scott

April 17th 2024

Real-world treatment with zanubrutinib was linked to longer treatment persistence, duration, and time to discontinuation in mantle cell lymphoma.

B-Cell Receptor Signaling Activity Portends Inferior Outcomes in MCL

By Kyle Doherty

April 17th 2024

B-cell receptor signaling characteristics were associated with worse outcomes in patients with mantle cell lymphoma.

Dr Pearse on the Utility of Pirtobrutinib in Relapsed/Refractory MCL

By William B. Pearse, MD

April 16th 2024

William B. Pearse, MD, discusses the current role of the BTK inhibitor pirtobrutinib in patients with relapsed/refractory mantle cell lymphoma.

Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine

Dr Coombs on Noncovalent BTK Inhibitors in Relapsed/Refractory MCL

By Catherine C. Coombs, MD

April 5th 2024

Catherine C. Coombs, MD, discusses the mechanism of action of noncovalent BTK inhibitors in patients with relapsed/refractory mantle cell lymphoma.

Dr Goy on Real-World Outcomes With CAR T-Cell Therapy in MCL

By Andre Goy, MD, John Theurer Cancer Center

March 29th 2024

Andre Goy, MD, discusses the implementation of CAR T-cell therapy in patients with relapsed/refractory mantle cell lymphoma.

CTL019 in MCL| Image Credit: © Dr_Microbe - stock.adobe.com

CTL019 Plus Ibrutinib is Feasible and Effective in Relapsed/Refractory MCL

By Kyle Doherty

March 29th 2024

CTL019 CAR T-cell therapy plus time-limited ibrutinib resulted in high complete response rates in relapsed/refractory mantle cell lymphoma.

Dr Phillips on Ongoing Research in High-Risk MCL

By Tycel Phillips, MD

March 28th 2024

Tycel Phillips, MD, MPH, discusses ongoing trials for patients with high-risk mantle cell lymphoma.

Observational Study Shows Frontline Ibrutinib With/Without Rituximab Is Safe and Effective in Low-Risk Mantle Cell Lymphoma

By Ashling Wahner

March 28th 2024

Ibrutinib with or without rituximab was effective and tolerable in patients with previously untreated, low-risk mantle cell lymphoma.

Dr Goy on Updated Data From ZUMA-2 With Brexu-Cel in MCL

By Andre Goy, MD, MS

March 27th 2024

Andre Goy, MD, discusses updated data from the phase 2 ZUMA-2 trial, highlighting the expanded-access ZUMA-18 study in MCL.

Cancer in the blood outbreak and treatment for malignant cells in a human body caused by carcinogens and genetics with a cancerous cell as an immunotherapy and leukemia or lymphoma symbol and medicalImage Credit: © freshidea - stock.adobe.com

Brexu-Cel Displays Superior Responses vs Pirtobrutinib in Relapsed/Refractory MCL Matching-Adjusted Indirect Comparison

By Kyle Doherty

March 22nd 2024

A matching-adjusted indirect comparison shows that brexu-cel is superior to pirtobrutinib regarding response and survival in relapsed/refractory MCL.

EZH2 Expression and TP53 Mutation Results in Inferior Outcomes in MCL

By Megan Hollasch

March 21st 2024

TP53 mutation and EZH2 expression negatively affect outcomes in mantle cell lymphoma, with a synergistic negative effect.

FDA Lifts Partial Clinical Hold on Trial Evaluating NX-2127 in R/R B-Cell Malignancies

By Chris Ryan

March 11th 2024

The FDA has lifted a partial clinical hold on a phase 1 trial evaluating NX-2127 in relapsed/refractory B-cell malignancies

Dr Phillips on Efforts to Clarify and Refine Management Approaches in Relapsed/Refractory MCL

By Tycel Phillips, MD

March 7th 2024

Tycel Phillips, MD, discusses efforts to clarify and refine the treatment paradigm of patients with mantle cell lymphoma.

Dr Phillips on Unmet Needs in Patients With Relapsed/Refractory MCL

By Tycel Phillips, MD

March 5th 2024

Tycel Phillips, MD, discusses unmet needs for patients with relapsed/refractory mantle cell lymphoma.

Brexu-Cel Delivers Prolonged OS Benefit in Relapsed/Refractory MCL

By Ashling Wahner

February 28th 2024

Andre H. Goy, MD, discusses how the ZUMA-18 trial data support the benefit of earlier-line use of brexucabtagene autoleucel in mantle cell lymphoma.

Revisit Every OncLive On Air Episode From January 2024

By Ashling Wahner

February 26th 2024

In case you missed it, read a recap of every episode of OncLive On Air recorded in January 2024.

Muhamad Alhaj Moustafa, MD, MS, hematologist, medical oncologist, Departments of Hematology and Oncology (Medical), Mayo Clinic

Dr Moustafa on Standard Treatment Approaches in MCL

By Muhamad Alhaj Moustafa, MD, MS

February 22nd 2024

Muhamad Alhaj Moustafa, MD, MS, discusses standard treatments for transplant-eligible and transplant-ineligible patients with mantle cell lymphoma.

M. Lia Palomba, MD, attending physician from Memorial Sloan Kettering Cancer Center

Liso-Cel Proves Active Across High-Risk MCL Subgroups

By Jordyn Sava

February 22nd 2024

Liso-cel may be an effective treatment option for patients with relapsed/refractory mantle cell lymphoma and high-risk features.

Dr Cohen on Treatment Considerations for Relapsed/Refractory MCL

By Jonathon B. Cohen, MD, MS

February 21st 2024

Jonathon B. Cohen, MD, MS, discusses treatment considerations for mantle cell lymphoma and the role of pirtobrutinib in the management of this disease.

$Ibrutinib Combined With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results From the Randomized Phase 3 SYMPATICO Study$

Ibrutinib Combined With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results From the Randomized Phase 3 SYMPATICO Study

By Michael Wang, MD

February 20th 2024

Michael Wang, MD, presents the primary analysis results from the multinational, randomized, double-blind, phase 3 SYMPATICO study comparing ibrutinib plus venetoclax vs ibrutinib plus placebo in patients with relapsed/refractory mantle cell lymphoma (R/R MCL).